Recent Insights into the Management of Behçet Syndrome

Abstract

Behçet syndrome (BS) is a multisystem vasculitis with variable vessel involvement that shows significant heterogeneity among patients in terms of clinical manifestations and disease course. Treatment choice and response are both influenced by this heterogeneity. BS treatments' main goals are to quickly suppress inflammatory exacerbations and prevent relapses in order to protect organ functions and provide good quality of life. Besides the long-term experience with steroids and traditional immunosuppressives, biologic drugs, especially TNF inhibitors, have gained increasing importance in the treatment of BS over the years. In this review, we aimed to give an overview of the studies with conventional and biological drugs with proven efficacy in the treatment of BS, as well as promising drugs and current management strategies according to clinical phenotypes.

The treatment principles and targets for intestinal Behcet’s disease

“…Certainly, the concrete medical treatment plans in intestinal BD such as reduction strategies of corticosteroid, advantages and disadvantages of different drugs, and application of biologic agents and conventional immunosuppressive agents were of the same importance which needs further discussion in the future. 65 , 66 …”